Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22017105 | 1.00 | HTR2A (0.30) | HTR2AHTR2CHTR2B | |
| SCHEMBL22017121 | 1.00 | HTR2A (0.30) | HTR2AHTR2CHTR2B | |
| SCHEMBL19918067 | 0.82 | — | — | |
| SCHEMBL22017413 | 0.82 | — | — | |
| SCHEMBL24390538 | 0.78 | — | — | |
| SCHEMBL28311780 | 0.75 | — | — | |
| SCHEMBL22017692 | 0.74 | — | — | |
| SCHEMBL22017106 | 0.74 | — | — | |
| SCHEMBL22016900 | 0.74 | — | — | |
| SCHEMBL6913249 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2023283453-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220135561-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11174256-B2 | Imidazopyridine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | HTR2A 3731/4885HTR2C 2362/4885HTR2B 3185/4885 |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | HTR2A 4619/4885HTR2C 4303/4885HTR2B 2861/4885 |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KRAS, HRAS, TP53 | HTR2A 4259/4885HTR2C 2559/4885HTR2B 4127/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | HTR2A 4712/4885HTR2C 4254/4885HTR2B 2972/4885 |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | HTR2A 1691/4885HTR2C 804/4885HTR2B 1758/4885 |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | HTR2A 4619/4885HTR2C 4303/4885HTR2B 2861/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | HTR2A 1691/4885HTR2C 804/4885HTR2B 1758/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | HTR2A 4619/4885HTR2C 4303/4885HTR2B 2861/4885 |
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | HTR2A 3546/4885HTR2C 2556/4885HTR2B 892/4885 |
| US-11174256-B2 | Imidazopyridine derivatives | TPMT, IRAK4, CFTR | HTR2A 3478/4885HTR2C 3175/4885HTR2B 3425/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | HTR2A 4619/4885HTR2C 4303/4885HTR2B 2861/4885 |
| US-20220135561-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | HTR2A 3478/4885HTR2C 3175/4885HTR2B 3425/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | HTR2A 1691/4885HTR2C 804/4885HTR2B 1758/4885 |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | HTR2A 3478/4885HTR2C 3175/4885HTR2B 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.